Applied Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy APLT

*Your capital is at risk

$0.0959

+0 (+0%)

At Close: Apr 28, 2026

Applied Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -62.17. In total, the insiders bought 12.37M and sold 10.56M APLT shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-62.17
● Buy	12.37M shares
● Sell	10.56M shares
44% Buy Activity Moderate Negative Correlation
Sell Signal High Confidence Feb 03, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -62.17. Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Feb 03, 2026 Sell	Stock Option (Right to Buy) D-Return	Kanter Stacy J. Director	Director	200 000 Value: $79.0K
Feb 03, 2026 Sell	Stock Option (Right to Buy) D-Return	Kanter Stacy J. Director	Director	16 500 Value: $17.3K
Feb 03, 2026 Sell	Common Stock U-Tender	Kanter Stacy J. Director	Director	42 500 Value: $4K
Feb 03, 2026 Sell	Common Stock D-Return	Kanter Stacy J. Director	Director	22 500 Value: $2K
Feb 03, 2026 Sell	Stock Option (Right to Buy) D-Return	Lerner Teena Director	Director	16 500 Value: $17.3K
Feb 03, 2026 Sell	Common Stock U-Tender	Lerner Teena Director	Director	82 922 Value: $7K
Feb 03, 2026 Sell	Common Stock U-Tender	Bailey Evan Prescott Chief Medical Officer	Officer	60 901 Value: $0
Feb 03, 2026 Sell	Common Stock D-Return	Bailey Evan Prescott Chief Medical Officer	Officer	1 235 915 Value: $108.8K
Feb 03, 2026 Sell	Stock Option (Right to Buy) D-Return	Skyler Jay S Director	Director	200 000 Value: $79.0K
Feb 03, 2026 Sell	Stock Option (Right to Buy) D-Return	Skyler Jay S Director	Director	16 500 Value: $17.3K
Feb 03, 2026 Sell	Common Stock U-Tender	Skyler Jay S Director	Director	42 500 Value: $4K
Feb 03, 2026 Sell	Common Stock D-Return	Skyler Jay S Director	Director	22 500 Value: $2K
Feb 03, 2026 Sell	Common Stock U-Tender	Chinoporos Constantine See Remarks	Officer	57 111 Value: $0
Feb 03, 2026 Sell	Common Stock D-Return	Hooks Corwin Dale Chief Commercial Officer	Officer	862 500 Value: $75.9K
Feb 03, 2026 Sell	Common Stock U-Tender	Hooks Corwin Dale Chief Commercial Officer	Officer	5 753 Value: $0
Feb 03, 2026 Sell	Common Stock D-Return	Chinoporos Constantine See Remarks	Officer	1 000 000 Value: $88.0K
Feb 03, 2026 Sell	Common Stock D-Return	Funtleyder Leslie D. Chief Financial Officer	C-Suite Officer	2 375 000 Value: $209.0K
Feb 03, 2026 Sell	Common Stock U-Tender	Funtleyder Leslie D. Chief Financial Officer	C-Suite Officer	152 959 Value: $0
Feb 03, 2026 Sell	Stock Option (Right to Buy) D-Return	Funtleyder Leslie D. Chief Financial Officer	C-Suite Officer	16 500 Value: $17.3K
Feb 03, 2026 Sell	Stock Option (Right to Buy) D-Return	Funtleyder Leslie D. Chief Financial Officer	C-Suite Officer	150 000 Value: $153.0K
Feb 03, 2026 Sell	Stock Option (Right to Buy) D-Return	Funtleyder Leslie D. Chief Financial Officer	C-Suite Officer	40 502 Value: $190.4K
Feb 03, 2026 Sell	Stock Option (Right to Buy) D-Return	Bailey Evan Prescott Chief Medical Officer	Officer	4 883 Value: $5K
Feb 03, 2026 Sell	Common Stock D-Return	Lerner Teena Director	Director	22 500 Value: $2K
Feb 03, 2026 Sell	Stock Option (Right to Buy) D-Return	Lerner Teena Director	Director	200 000 Value: $79.0K
Feb 03, 2026 Sell	Stock Option (Right to Buy) D-Return	Lerner Teena Director	Director	23 941 Value: $112.5K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT APPLIED THERAPEUTICS INC.

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the...

Read Full Profile Here